Biotech Values

[dewophile]

I responded in a more round about way when I mentioned the biobucks ENTA could probably command if it needed to partner the hep B program. I had the new drug in mind as part of the package specifically because of the deals RNAi companies have struck in hep B (JNJ, Roche, etc.). So clearly large pharma likes this general MOA as a complementary piece